Drugs /

e6201

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
A synthetic, fungal metabolite analogue inhibitor of mitogen-activated protein kinase kinase 1 (MEK-1) and mitogen-activated protein kinase kinase kinase 1 (MEKK-1) with potential antipsoriatic and antineoplastic activities. MEK-1/MEKK-1 inhibitor E6201 specifically binds to and inhibits the activities of MEK-1 and MEKK-1, which may result in the inhibition of tumor cell proliferation. MEK-1 and MEKK-1 are key components in the RAS/RAF/MEK/MAPK signaling pathway, which regulates cell proliferation and is frequently activated in human cancers.

Clinical Trials

View Clinical Trials for e6201

E6201 has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating e6201, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open).

BRAF Codon 600 Missense, Complex karyotype, and FLT3 Mutation are the most frequent biomarker inclusion criteria for e6201 clinical trials.

Acute myeloid leukemia, chronic myelomonocytic leukemia, and melanoma are the most common diseases being investigated in e6201 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating E6201
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating E6201
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating e6201 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
mek-1/mekk-1 inhibitor e6201
Drug Categories [2]:
MEK inhibitors, Serine/threonine kinase inhibitors, Tyrosine kinase inhibitors
Drug Target(s) [2]:
FLT3, MAP2K1, MAP3K1
NCIT ID [1]:
C79848

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.